Niv Yaron
Department of Gastroenterology, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel.
Eur J Gastroenterol Hepatol. 2017 Dec;29(12):1327-1331. doi: 10.1097/MEG.0000000000000994.
The WHO published a new classification of colonic polyps in 2010, including the group of serrated polyps, which can be divided into hyperplastic polyps (HP), traditional serrated adenomas, and sessile serrated adenomas (SSA) or polyps. To assess the rate of re-diagnosis of HP to SSA and to look for possible predictors for changing the diagnosis. English Medical literature searches were performed for 'reassessment' OR 'reclassification' AND 'hyperplastic polyp' OR 'sessile serrated adenoma' till 31 January 2017. PRISMA guidelines for systematic reviews were followed. Studies that included a precise re-diagnosis of HP into SSA were included. We also looked for predictors of SSA diagnosis such as polyp location and size, patient sex and age, and synchronous advanced adenoma. Altogether, we found 220 eligible studies; 212 were excluded as they did not fulfill the inclusion criteria and we were left with eight studies including 2625 patients. The odds ratio for the number of polyps with changed pathological diagnosis from HP to SSA was 0.112 with 95% confidence interval (CI): 0.099-0.126 (P<0.0001) or 11.2%. Heterogeneity between studies was significant with Q=199.4, d.f. (Q)=9, P<0.0001, and I=95.486%. The odds ratio for changing the pathological diagnosis from HP to SSA for polyp proximal location and polyp size more than 5 mm were 4.401, 95% CI: 2.784-6.958, P<0.0001, and 8.336, 95% CI: 4.963-15.571, P<0.0001, respectively. Endoscopists and pathologists should be aware of the SSA diagnosis when finding HPs larger than 5 mm in the right colon. The diagnosis of HP in these cases should be reassessed by experienced gastrointestinal pathologists.
世界卫生组织于2010年发布了结肠息肉的新分类,其中包括锯齿状息肉组,该组可分为增生性息肉(HP)、传统锯齿状腺瘤和无蒂锯齿状腺瘤(SSA)或息肉。为评估HP重新诊断为SSA的比率,并寻找可能改变诊断结果的预测因素。截至2017年1月31日,我们检索了英文医学文献,检索词为“重新评估”或“重新分类”以及“增生性息肉”或“无蒂锯齿状腺瘤”。我们遵循PRISMA系统评价指南。纳入了对HP精确重新诊断为SSA的研究。我们还寻找了SSA诊断的预测因素,如息肉位置和大小、患者性别和年龄以及同步进展性腺瘤。我们共找到220项符合条件的研究;212项因不符合纳入标准而被排除,最终剩下8项研究,共2625例患者。病理诊断从HP改变为SSA的息肉数量的比值比为0.112,95%置信区间(CI):0.099 - 0.126(P<0.0001),即11.2%。研究间异质性显著,Q = 199.4,自由度(Q)= 9,P<0.0001,I = 95.486%。息肉位于近端和息肉大小超过5毫米时,病理诊断从HP改变为SSA的比值比分别为4.401,95%CI:2.784 - 6.958,P<0.0001,以及8.336,95%CI:4.963 - 15.571,P<0.0001。内镜医师和病理学家在右半结肠发现大于5毫米的HP时应注意SSA的诊断。在这些病例中,HP的诊断应由经验丰富的胃肠病理学家重新评估。